Member Login
  1. Stocks
    2. /
  2. Hikma Pharmaceuticals PLC (LSE: HIK)
    3. /

LSE:HIK (Hikma Pharmaceuticals PLC)

About HIK

Hikma is an international pharmaceutical company conducting operations through three businesses: generic pharmaceuticals, branded pharmaceuticals and injectable pharmaceuticals. The majority of Hikmas operations are in the United States, the Middle East and North Africa Region and Europe.
Financial Market Data copyright © 2025 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • Hikma Pharmaceuticals PLC (LSE: HIK) Latest News

    Investing Articles

    Which of these Footsie healthcare stars should you buy after today’s news?

    | Royston Wild

    Royston Wild discusses the investment prospects of two Footsie medical giants.

    Read more »

    Investing Articles

    Why did shares in Hikma Pharmaceuticals plc and GlaxoSmithKline plc crash last week?

    | Rupert Hargreaves

    Shares in GlaxoSmithKline plc (LON: GSK) and Hikma Pharmaceuticals plc (LON: HIK) are crashing but should you sell?

    Read more »

    Investing Articles

    Should you ditch these Footsie pharma stocks right now!

    | G A Chester

    Are these blue chips now too dicey to hold?

    Read more »

    Investing Articles

    2 firms to retire on

    | Kevin Godbold

    Here’s an elegant strategy for a financially worry-free retirement.

    Read more »

    Investing Articles

    Top stocks for November

    | The Motley Fool Staff

    We asked our analysts to share their top stock picks for the coming month.

    Read more »

    Investing Articles

    Directors are buying these high growth stocks – should you follow them?

    | Edward Sheldon, CFA

    Edward Sheldon looks at two stocks that have seen sizeable director's purchases in September.

    Read more »

    Investing Articles

    Are these the FTSE 100’s best contrarian bets?

    | Royston Wild

    Royston Wild reveals two FTSE 100 (INDEXFTSE: UKX) giants well overdue for a share price upturn.

    Read more »

    Investing Articles

    Should you buy GlaxoSmithKline plc after its change in CEO?

    | Peter Stephens

    Is GlaxoSmithKline plc (LON: GSK) more or less appealing after a change in senior management?

    Read more »

    Investing Articles

    Is this the best healthcare stock money can buy after today’s update?

    | Peter Stephens

    Should you buy this stock or a sector peer following today's news?

    Read more »

    Investing Articles

    These FTSE 100 giants sank in August! Can they bounce back?

    | Royston Wild

    Royston Wild looks at the share price prospects of three recent FTSE 100 (INDEXFTSE: UKX) fallers.

    Read more »

    Investing Articles

    Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?

    | Edward Sheldon, CFA

    Edward Sheldon looks at Hikma Pharmaceuticals plc's (LON: HIK) interim results statement and examines whether the long-term growth story is…

    Read more »

    Investing Articles

    Is this stock the best buy in its sector following today’s update?

    | Peter Stephens

    Should you buy this stock over two industry peers?

    Read more »